Fresenius SE is making up ground


The Fresenius SE share rose in XETRA trading. Most recently, the price of the paper rose by 1.2 percent to EUR 38.68. This makes the security one of the current winners in the DAX, which is currently trading at 13,776 points. In the meantime, the Fresenius SE share even rose to EUR 39.04. The stock started the XETRA trading day at EUR 38.60. So far, 329,353 Fresenius SE shares have been bought or sold via XETRA.

With a price gain of up to EUR 51.54, the stock reached a 52-week high on February 20, 2020. On March 19, 2020, the share fell to EUR 24.25, falling to a 52-week low.

On average, experts calculated a price target of EUR 49.49 for the Fresenius SE share. Experts estimate the Fresenius SE profit for 2021 at EUR 3.52 per share.

Fresenius SE is an international health group that offers products and services for hospitals, outpatient medical care for patients and dialysis. Further fields of work are the hospital carrier business as well as engineering and services for various health facilities. The Fresenius Group comprises four companies that operate independently around the world: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. Fresenius Medical Care is the world’s leading provider of products and services for patients with chronic kidney failure. Fresenius Kabi is the market leader in infusion therapy and clinical nutrition in Europe. The Helios Kliniken Group is one of the largest and medically leading clinic companies in Europe and specializes in the operation and operational management of hospitals. Vamed is active worldwide in the project and management business of healthcare facilities. These include hospitals, health centers, thermal baths and wellness centers. In addition, information technology services are offered through Fresenius NetCare.

The latest news on Fresenius SE shares

Fresenius share significantly lighter: Fresenius Helios takes over Eugin Clinic Group

BioNTech, CureVac & Co: How investors can participate in the vaccine trend – and what they risk with it

Fresenius is on the road to recovery editorial team


Current certificates from

The base prospectus as well as the final terms and the key information sheets are available here: JJ0GFY, JC5R85. Please also note the further information ** on this advertisement.

Image sources: Fresenius

Source link


Please enter your comment!
Please enter your name here